Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury

[1]  P. Tuinman,et al.  Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies. , 2017, Annals of translational medicine.

[2]  J. Wetterslev,et al.  Antithrombin III for critically ill patients. , 2016, The Cochrane database of systematic reviews.

[3]  M. Ehlers.  Immune-modulating effects of alpha-1 antitrypsin , 2014, Biological chemistry.

[4]  A. Girbes,et al.  Recombinant Human Activated Protein C in the Treatment of Acute Respiratory Distress Syndrome: A Randomized Clinical Trial , 2014, PloS one.

[5]  Haibo Zhang,et al.  α1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  T. Welte,et al.  Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase , 2013, Proceedings of the National Academy of Sciences.

[7]  P. Tuinman,et al.  High-Dose Acetylsalicylic Acid Is Superior to Low-Dose as Well as to Clopidogrel in Preventing Lipopolysaccharide-Induced Lung Injury in Mice , 2013, Shock.

[8]  L. Shapiro,et al.  Alpha-1 Antitrypsin Reduces Severity of Pseudomonas Pneumonia in Mice and Inhibits Epithelial Barrier Disruption and Pseudomonas Invasion of Respiratory Epithelial Cells , 2013, Front. Public Health.

[9]  P. Tuinman,et al.  Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome , 2013, Journal of Thrombosis and Haemostasis.

[10]  R. Chambers,et al.  Coagulation cascade proteinases in lung injury and fibrosis. , 2012, Proceedings of the American Thoracic Society.

[11]  P. Tuinman,et al.  Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations , 2012, Critical Care.

[12]  Arthur S Slutsky,et al.  Plasma‐derived human antithrombin attenuates ventilator‐induced coagulopathy but not inflammation in a Streptococcus pneumoniae pneumonia model in rats , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  C. Vogelmeier,et al.  The discovery of α1-antitrypsin and its role in health and disease. , 2011, Respiratory medicine.

[14]  P. Tsai,et al.  Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats. , 2011, The Journal of surgical research.

[15]  O. Soehnlein,et al.  Contribution of Neutrophils to Acute Lung Injury , 2011, Molecular medicine.

[16]  M. Matthay,et al.  The acute respiratory distress syndrome: pathogenesis and treatment. , 2011, Annual review of pathology.

[17]  T. van der Poll,et al.  Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[18]  S. Matalon,et al.  Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo , 2010, Inflammation Research.

[19]  T. Martin,et al.  Animal models of acute lung injury , 2008, American journal of physiology. Lung cellular and molecular physiology.

[20]  T. van der Poll,et al.  Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats* , 2008, Critical care medicine.

[21]  J. Wetterslev,et al.  Antithrombin III for critically ill patients. , 2008, The Cochrane database of systematic reviews.

[22]  T. van der Poll,et al.  Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation , 2007, European Respiratory Journal.

[23]  P. Parsons,et al.  Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome* , 2006, Critical care medicine.

[24]  Arthur S Slutsky,et al.  Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—A review , 2006, Critical care medicine.

[25]  M. Rojas,et al.  Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[26]  C. Wiedermann,et al.  Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin , 2003, Thrombosis and Haemostasis.

[27]  M. Matthay,et al.  Protein C and thrombomodulin in human acute lung injury. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[28]  A. Staubitz,et al.  Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. , 2002, Blood.

[29]  J. Römisch,et al.  Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. , 2002, Journal of cell science.

[30]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[31]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[32]  S. Opal,et al.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.

[33]  M. Uchiba,et al.  Antithrombin III (AT III) Prevents LPS-Induced Pulmonary Vascular Injury: Novel Biological Activity of AT III , 1997, Seminars in thrombosis and hemostasis.

[34]  K. Takatsuki,et al.  Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III , 1996 .

[35]  B. Wallaert,et al.  Oxidative inactivation of alpha 1-proteinase inhibitor by alveolar epithelial type II cells. , 1993, Journal of applied physiology.

[36]  E. Te,et al.  Synergistic protection from lung damage by combining antithrombin-III and alpha 1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. , 1988 .

[37]  C. Cochrane.  Alpha-1-proteinase inhibitor in inflammatory states of humans and laboratory animals. , 1988, The American journal of medicine.

[38]  T. Emerson,et al.  Synergistic protection from lung damage by combining antithrombin-III and alpha 1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. , 1988, Circulatory shock.